- Home
- ORMP vs MRSN Comparison
ORMP vs MRSN Comparison
Compare ORMP & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- MRSN
- Stock Information
- Founded
- ORMP 2002
- MRSN 2001
- Country
- ORMP United States
- MRSN United States
- Employees
- ORMP N/A
- MRSN N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ORMP Health Care
- MRSN Health Care
- Exchange
- ORMP Nasdaq
- MRSN Nasdaq
- Market Cap
- ORMP 84.3M
- MRSN 71.9M
- IPO Year
- ORMP N/A
- MRSN 2017
- Fundamental
- Price
- ORMP $2.62
- MRSN $0.48
- Analyst Decision
- ORMP Hold
- MRSN Buy
- Analyst Count
- ORMP 1
- MRSN 4
- Target Price
- ORMP N/A
- MRSN $4.33
- AVG Volume (30 Days)
- ORMP 573.2K
- MRSN 3.8M
- Earning Date
- ORMP 03-18-2025
- MRSN 03-03-2025
- Dividend Yield
- ORMP N/A
- MRSN N/A
- EPS Growth
- ORMP N/A
- MRSN N/A
- EPS
- ORMP 0.11
- MRSN N/A
- Revenue
- ORMP N/A
- MRSN $40,497,000.00
- Revenue This Year
- ORMP N/A
- MRSN N/A
- Revenue Next Year
- ORMP N/A
- MRSN $67.68
- P/E Ratio
- ORMP $22.93
- MRSN N/A
- Revenue Growth
- ORMP N/A
- MRSN 9.88
- 52 Week Low
- ORMP $1.96
- MRSN $0.45
- 52 Week High
- ORMP $3.14
- MRSN $5.96
- Technical
- Relative Strength Index (RSI)
- ORMP 66.16
- MRSN 35.88
- Support Level
- ORMP $1.96
- MRSN $0.49
- Resistance Level
- ORMP $2.68
- MRSN $0.56
- Average True Range (ATR)
- ORMP 0.15
- MRSN 0.05
- MACD
- ORMP 0.05
- MRSN 0.02
- Stochastic Oscillator
- ORMP 91.67
- MRSN 28.11
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.